Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

Rafat Abonour; Robert M Rifkin; Cristina Gasparetto; Kathleen Toomey; Brian G M Durie; James W Hardin; Howard R Terebelo; Sundar Jagannath; Mohit Narang; Sikander Ailawadhi; James L Omel; Hans C Lee; Shankar Srinivasan; Amani Kitali; Amit Agarwal; Lynne Wagner; CONNECT MM Registry Investigators

doi:10.1111/bjh.17131

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect^® MM Registry

Br J Haematol. 2021 Apr;193(1):93-100. doi: 10.1111/bjh.17131. Epub 2020 Oct 29.

Authors

Rafat Abonour¹, Robert M Rifkin², Cristina Gasparetto³, Kathleen Toomey⁴, Brian G M Durie⁵, James W Hardin⁶, Howard R Terebelo⁷, Sundar Jagannath⁸, Mohit Narang⁹, Sikander Ailawadhi¹⁰, James L Omel¹¹, Hans C Lee¹², Shankar Srinivasan¹³, Amani Kitali¹³, Amit Agarwal¹³, Lynne Wagner¹⁴; CONNECT MM Registry Investigators

Affiliations

¹ Indiana University, Indianapolis, IN, USA.
² Rocky Mountain Cancer Centers US Oncology, Denver, CO, USA.
³ Duke University Medical Center, Durham, NC, USA.
⁴ Steeplechase Cancer Center, Somerville, NJ, USA.
⁵ Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁶ University of South Carolina, Columbia, SC, USA.
⁷ Providence Cancer Institute, Southfield, MI, USA.
⁸ Mount Sinai Hospital, New York, NY, USA.
⁹ US Oncology Research, Columbia, MD, USA.
¹⁰ Mayo Clinic, Jacksonville, FL, USA.
¹¹ Myeloma Research Advocate/Advisor, Grand Island, NE, USA.
¹² The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹³ Bristol Myers Squibb, Princeton, NJ, USA.
¹⁴ Wake Forest School of Medicine, Winston-Salem, NC, USA.

Abstract

Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect^® MM Registry, a large, USA, multicentre, prospective observational cohort study. Functional Assessment of Cancer Therapy-Multiple Myeloma subscale, EuroQol-5D overall score and Bone Pain Inventory HRQoL scores were significantly improved with RVd versus Vd/VMP. Serious adverse event rates were similar in all groups. Treatment with RVd maintained HRQoL in this real-world, largely community-based population of patients with NDMM.

Keywords: health-related quality of life; lenalidomide; multiple myeloma; real-world evidence.

Publication types

Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors / adverse effects
Angiogenesis Inhibitors / therapeutic use
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Agents, Alkylating / therapeutic use
Antineoplastic Agents, Hormonal / adverse effects
Antineoplastic Agents, Hormonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / adverse effects
Bortezomib / therapeutic use
Case-Control Studies
Dexamethasone / adverse effects
Dexamethasone / therapeutic use
Female
Humans
Lenalidomide / adverse effects
Lenalidomide / therapeutic use
Male
Melphalan / adverse effects
Melphalan / therapeutic use
Middle Aged
Multiple Myeloma / diagnosis*
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Multiple Myeloma / psychology*
Prednisone / adverse effects
Prednisone / therapeutic use
Prospective Studies
Quality of Life / psychology
Registries
Safety
Stem Cell Transplantation / standards

Substances

Angiogenesis Inhibitors
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Bortezomib
Dexamethasone
Lenalidomide
Melphalan
Prednisone

Grants and funding

Celgene Corporation and Bristol Myers Squibb